Introduction
============

The occurrence of cervical lymph node metastasis in patients with head and neck cancers are very common.[@b1-ott-8-1291] The presence of cervical lymph node metastasis may affect the optimal treatment choice as well as prognosis in patients.[@b2-ott-8-1291] Management of patients presenting with cervical lymph node metastasis includes selective or radical neck dissection, followed by radiotherapy and/or chemotherapy depending on the pathological findings of the nodes.[@b3-ott-8-1291]--[@b5-ott-8-1291] Besides, the detection of cervical lymph node metastasis is very important for predicting prognosis in patients with head and neck cancers.[@b6-ott-8-1291]--[@b8-ott-8-1291]

Many imaging techniques exist for identifying cervical lymph node metastasis in patients with head and neck cancers.[@b9-ott-8-1291]--[@b12-ott-8-1291] Among them, computed tomography (CT) and magnetic resonance imaging (MRI) are the most widely used tools.[@b13-ott-8-1291] Both of them have improved accuracy of nodal staging over clinical palpation and the nodes which are clinically occulted can be visualized through these techniques.[@b14-ott-8-1291] Usually the cervical lymph nodes demonstrate similar density as muscle on pre-contrast images of CT examination, and they can be separated from adjacent vessels by their differential enhancement after contrast administration.[@b15-ott-8-1291] On the other hand, MRI is considered to have similar accuracy for identifying the cervical lymph node metastasis of head and neck cancer.[@b16-ott-8-1291],[@b17-ott-8-1291] Because of the intrinsic high soft-tissue discrimination, MRI has become the preferred method for evaluating the soft tissues of the head and neck recently.[@b18-ott-8-1291] Under current health care settings, the routine practice for evaluating patients with head and neck cancer is to perform either CT or MRI, but not both.[@b19-ott-8-1291] Thus, to determine whether one of the two techniques is superior to the other is critical for providing guidance for clinical practice. Besides, since relevant studies utilized very different diagnostic criteria, it is warranted to determine the unified criteria that are most appropriate. A systematic review to assess all available evidence is thus needed for providing a comprehensive evaluation for these aims.

The aim of this study was thus to compare CT and MRI for detecting cervical lymph node metastasis in patients with head and neck cancer and to establish the unified diagnostic criteria by performing a systematic review and meta-analysis.

Methods
=======

Inclusion criteria
------------------

The inclusion criteria were as follows: a) types of study: diagnostic accuracy test studies designed as cohort studies; b) participants: patients with biopsy proven head and neck cancers who would undergo neck dissection; c) index tests: CT and/or MRI; d) target condition: cervical lymph node metastasis; e) reference standard: histopathology examination; f) outcome: rates of true positive, false positive, false negative, and true negative or related data that could be used to calculate them.

Literature search
-----------------

With no language restriction, the following databases were searched for retrieving studies: MEDLINE (1948 to 25 January 2014), EMBASE (1980 to 25 January 2014), China National Knowledge Infrastructure (1994 to 25 January 2014), VIP Chinese Journal Database (1989 to 25 January 2014), and Chinainfo (1998 to 25 January 2014).

The search strategy was optimized for all consulted databases, taking into account the differences in the various controlled vocabularies as well as the differences of database-specific technical variations.[@b20-ott-8-1291] Once relevant articles were identified, their reference lists were searched for additional articles. Both Medical Subject Headings (MeSH) and free text words were used in the search strategy with the following MeSH terms: "head and neck neoplasm", "neoplasm metastases", "SEN and SPE", "Tomography, Spiral Computed" and "Magnetic Resonance Imaging".

Study selection
---------------

Two reviewers independently examined the titles and abstracts of each search record to remove obviously irrelevant ones, and then retrieved the full text articles for potentially eligible articles. The full-texts were further examined according to the inclusion criteria. Discrepancies were resolved by consensus.

Data extraction
---------------

A standardized data extraction form was used by two authors independently for data extraction from included studies. Discrepancies were resolved by discussion, with input from a third author. The contents of the form included: name of first author, publication year, country, participants' age, sex, number of included patients, tumor location, unit, details of CT and/or MRI, study design (prospective or retrospective).

Quality assessment
------------------

The methodological quality of included studies was assessed by The Quality Assessment Diagnostic Accuracy Studies statement-2 (QUADAS-2),[@b21-ott-8-1291] which included four domains: patient selection, index test, reference standard, and flow and timing. Each domain was assessed in terms of risk of bias and the first three were assessed in terms of concerns regarding applicability. Signaling questions were included to assist judgments on risk of bias. The signaling questions in the QUADAS-2 were presented as shown in [Table 1](#t1-ott-8-1291){ref-type="table"}. The result for each item was categorized as yes (Y), unclear (U), or no (N). The summary risk of bias for each study was categorized as low (A), unclear (B), or high (C).

Meta-analysis
-------------

Measures of diagnostic efficacy of CT and/or MRI included sensitivity (SEN), specificity (SPE), positive likelihood ratio (+LR), negative likelihood ratio (−LR), accuracy (ACC), and diagnostic odds ratios (DOR) with 95% confidence intervals (CIs). Summary receiver operating characteristic (SROC) curves were then drawn. The area under the curve (AUC) and Q\* (the point where SEN is equal to SPE on the SROC curve) were calculated.

To detect any differences for SEN, SPE, AUC, and Q\* between CT and MRI, a Z-test was conducted (Z= (VAL1--VAL2)/SQRT (SE1[@b2-ott-8-1291]+SE2[@b2-ott-8-1291]). The test standard was set at α=0.05. VAL indicates the mean of SEN, SPE, AUC or Q\* of the CT or MRI and SE indicates the standard error of the corresponding variable.

Heterogeneity analysis
----------------------

Heterogeneity between studies was evaluated by *I*^2^ statistic.[@b22-ott-8-1291],[@b23-ott-8-1291] If *I*^2^≤50% and *P*≥0.10, the heterogeneity was considered not significant and in such case the fixed-effects model would be used in meta-analysis. Otherwise, the random-effects model would be used.[@b24-ott-8-1291],[@b25-ott-8-1291]

Meta-regression
---------------

Meta-regression was used to determine any potential source of heterogeneity that might influence the overall assessment. The test standard for meta-regression was set at α=0.10. Relevant variables which might cause heterogeneities were tested, and any suggested sources of heterogeneity were considered as proof for a subgroup analysis. Variables detected by meta-regression included publication year (0= published before 2000; 1= published in or after 2000), race (0= Mongolia; 1= Caucasian), study type (0= retrospective; 1= prospective), risk of bias (0= high; 1= unclear; 2= low), blinding of the radiologists (0= no or unclear; 1= yes) and blinding of the pathologists (0= no or unclear; 1= yes). Meta-disc 1.4 and STATA 11.0 (StataCorp LP, College Station, TX, USA) were used to perform the statistical analyses.[@b26-ott-8-1291],[@b27-ott-8-1291]

Results
=======

Selection of literature
-----------------------

The computerized and manual search retrieved a total of 306 articles. After assessing the titles and abstracts, 144 articles were found to be potentially relevant. After the full text assessment, 63 studies met the inclusion criteria and were included in this meta-analysis ([Figure 1](#f1-ott-8-1291){ref-type="fig"}).[@b28-ott-8-1291]--[@b90-ott-8-1291]

Study characteristics
---------------------

Of the 63 included studies, 24 were retrospective and 39 were prospective. A total of 3,029 participants were involved in these studies. Among those patients, 1,044 underwent both CT and MRI examination, 2,395 underwent MRI examination, and 1,678 underwent CT examination. Three kinds of unit of analysis were used, including node, neck level (the neck was classified as five levels according to anatomical landmarks), and patients. When node was considered as the unit of analysis, available studies involved 22 with CT and 30 with MRI. When neck level was considered as the unit of analysis, eight studies with CT and 16 with MRI were available. When patient was considered as the unit of analysis, available studies included eight with CT and eleven with MRI. The tumor locations included floor of mouth, nasopharynx, retromolar trigonum, mandibule, maxilla, supra-glottic larynx, oropharynx, laryngopharynx, hypopharynx, parotid gland, submandibular gland, tonsil, thyroid gland, cervical esophageal, paranasal sinuses et al. The characteristics of included studies are listed in [Table 2](#t2-ott-8-1291){ref-type="table"}.

Quality of included studies
---------------------------

All included studies had fairly good applicability. For the risk of bias assessment, only two studies had a low risk of bias, five had a high risk, and 56 had an unclear risk ([Table 3](#t3-ott-8-1291){ref-type="table"}).

Comparison of CT and MRI in detecting cervical lymph node metastasis with node as unit of analysis
--------------------------------------------------------------------------------------------------

For CT, meta-regression analysis showed that the diagnostic efficacy was not affected by any of the tested variables. These variables thus did not account for heterogeneity between studies. After pooling 22 studies, we detected that CT had a mean (CI) SEN of 0.77 (95% CI 0.73--0.80), SPE of 0.85 (0.84--0.87), +LR of 3.84 (2.51--5.87), −LR of 0.34 (0.24--0.27), ACC of 0.8357, and DOR of 13.57 (6.99--26.33). The SROC was demonstrated in [Figure 2](#f2-ott-8-1291){ref-type="fig"} and the AUC was 0.8429 and Q\* was 0.7745. For MRI, meta-regression analysis also showed that the diagnostic efficacy was not affected by any of the tested variables. After pooling 30 studies, we identified that MRI had a mean (CI) SEN of 0.72 (0.70--0.74), SPE of 0.84 (0.83--0.85), +LR of 5.06 (3.72--6.88), −LR of 0.27 (0.21--0.34), ACC of 0.8126, and DOR of 25.21 (15.97--39.80). The SROC is shown in [Figure 2](#f2-ott-8-1291){ref-type="fig"} and the AUC was 0.9054 and Q\* was 0.8371.

By comparing the diagnostic efficacy between CT and MRI when node was treated as the unit of analysis, the results indicated that CT had a higher SEN, although the SPE and summarized diagnostic efficacy were comparable. The details are listed in [Table 4](#t4-ott-8-1291){ref-type="table"}.

Comparison of CT and MRI in detecting cervical lymph node metastasis with neck level as unit of analysis
--------------------------------------------------------------------------------------------------------

For MRI, meta-regression analysis detected that none of the tested variables accounted for heterogeneity between studies. After pooling 16 studies, it was detected that MRI had a mean (CI) SEN of 0.80 (0.77--0.82), SPE of 0.81 (0.80--0.82), +LR of 5.34 (3.24--8.82), −LR of 0.27 (0.20--0.37), ACC of 0.5257, DOR of 24.61 (12.21--49.61) and the AUC was 0.8860 and Q\* was 0.8165 ([Figure 3](#f3-ott-8-1291){ref-type="fig"}). For CT, similarly none of the tested variables accounted for heterogeneity. The pooling of available studies identified that CT had a mean (CI) SEN of 0.80 (0.75--0.84), SPE of 0.72 (0.69--0.74), +LR of 5.60 (2.13--14.73), −LR of 0.26 (0.19--0.36), ACC of 0.6888, DOR of 23.76 (7.87--71.79) and the AUC was 0.8787 and Q\* was 0.8091 ([Figure 3](#f3-ott-8-1291){ref-type="fig"}).

The comparison between CT and MRI showed that MRI had significantly higher SPE than CT while the other variables were comparable between these two techniques ([Table 4](#t4-ott-8-1291){ref-type="table"}).

Comparison of CT and MRI in detecting cervical lymph node metastasis with patient as unit of analysis
-----------------------------------------------------------------------------------------------------

For the two studies, the pooled results showed that CT had a mean (CI): SEN, 0.81 (0.65--0.92); SPE, 0.35 (0.24--0.42); +LR, 1.14 (0.87--1.50); −LR, 0.70 (0.32--1.52); DOR, 1.66 (0.57--4.82) ([Figure S1](#SD1-ott-8-1291){ref-type="supplementary-material"}). For MRI, which included ten studies, meta-regression analysis showed that study type significantly affected the assessment of diagnostic efficacy (*P*=0.04) ([Table 5](#t5-ott-8-1291){ref-type="table"}). Based on the subgroup analysis according to study types, for the four retrospective studies, the pooled results indicated that MRI had a mean (CI) SEN, 0.77 (0.69--0.85); SPE, 0.48 (0.42--0.55); +CR, 2.42 (0.99--5.91); −CR, 0.54 (0.27--1.06); DOR, 5.24 (0.96--28.55) ([Figure S2](#SD2-ott-8-1291){ref-type="supplementary-material"}). For the five prospective studies, the pooled results showed that MRI had a mean (CI) SEN, 0.80 (0.72--0.86); SPE, 0.35 (0.67--0.86); +LR, 2.79 (1.44--5.40); −LR, 0.25 (0.08--0.76); DOR, 14.63 (3.64--58.70) ([Figure S3](#SD3-ott-8-1291){ref-type="supplementary-material"}). Pooling of the overall nine studies indicated the mean (CI) values for the following parameters to be: SEN, 0.79 (0.73--0.84); SPE, 0.56 (0.51--0.62); +LR, 2.64 (1.30--5.34); −LR, 0.37(0.20--0.71); DOR, 8.87 (2.42--32.55); AUC (0.8158); Q\* (0.7498) ([Figure S4](#SD4-ott-8-1291){ref-type="supplementary-material"}).

The comparison between CT and MRI showed that MRI had significantly higher AUC than CT while the other variables demonstrated no statistical significance between them. The details are listed in [Table 4](#t4-ott-8-1291){ref-type="table"}.

Lymph node size criteria
------------------------

The size of metastatic lymph nodes used as diagnostic criteria of MRI and CT varied considerably among studies and among different neck levels ([Table S1](#SD5-ott-8-1291){ref-type="supplementary-material"}). To determine the best diagnostic criteria, a meta-analysis was conducted for different neck levels with lymph node unit data. For each neck level, the SROC curve was drawn to show the diagnostic efficacy of MRI for different node sizes ([Figure 4](#f4-ott-8-1291){ref-type="fig"}). The results revealed that the minimal axial diameter of 10 mm in lymph node-bearing regions could be considered as the best size criterion for assessing cervical lymph node metastasis in patients with head and neck cancer ([Table S2](#SD6-ott-8-1291){ref-type="supplementary-material"}). For CT, the suggested criterion was 12 mm ([Table S3](#SD7-ott-8-1291){ref-type="supplementary-material"}). Considering the limited number of studies for CT, SROC curves were not drawn.

Discussion
==========

Head and neck cancer is a common malignant neoplasm worldwide.[@b1-ott-8-1291] One of the most important factors that influences treatment approaches and therapeutic outcomes for patients with head and neck cancer is the presence of metastatic cervical lymph node. The accurate detection of the cervical lymph node metastasis is thus very important.[@b91-ott-8-1291],[@b92-ott-8-1291] Clinical palpation used to be the method to detect cervical nodal metastasis before the development of imaging technologies. However, studies have shown that both the SEN and the SPE of this technique were unsatisfactory, with a high false positive rate of 25%--51%. The improvements in imaging technologies may make it possible for cervical lymph nodes metastasis in head and neck cancer patients can be effectively diagnosed, especially with CT and MRI.[@b11-ott-8-1291],[@b12-ott-8-1291],[@b93-ott-8-1291]--[@b96-ott-8-1291] However, under current health care settings usually only one imaging technique will be performed. Thus a systematic evaluation regarding whether one of the two imaging techniques (CT and MRI) can have a better efficacy than the other will be critical to better guide the clinical practice.

In our systematic review and meta-analysis, we comprehensively evaluated all available evidence from 63 studies for evaluating this question whether one of the two imaging techniques (CT and MRI) can have a better efficacy. Besides pooling results from available studies, we assessed potential sources of heterogeneities via meta-regression and conducted sub-group analyses for significant heterogeneity sources detected. Our meta-analyses suggested that CT had a higher SEN than MRI when node was used as unit of analysis; MRI had a higher SPE when neck level was used as unit of analysis; and MRI had a higher AUC when patient was used as unit of analysis. Our findings showed that CT and MRI are effective tools for detecting the cervical lymph node metastasis in patients with head and neck cancer. Since the diagnostic criteria presented in relevant studies varied significantly, we also summarized available evidence to reveal the most appropriate ones for these two techniques, respectively. Usually, the diagnosis of metastatic cervical lymph nodes consisted of two parts, namely, structural and size changes. The structural changes included central necrosis or cystic degeneration, spherical (rather than flat or bean) shape, or abnormal grouping of nodes (a cluster of three or more lymph nodes of borderline size). In different studies, the description of the structural changes differed only mildly. However, the criteria for sizes differed considerably. Most authors recommended using the minimal axial diameter to assess metastasis. The criterion for minimal axial diameter varied between 5 to 15 mm. Our meta-analysis showed that the minimal axial diameter of 10 mm in lymph node-bearing regions could be considered as the best criterion for assessing cervical lymph node metastasis in patients with head and neck cancer for MRI, compared to 12 mm for CT. Several limitations should be acknowledged for the interpretation of our findings. Firstly, although we conducted meta-regression analyses and showed that the assessed variables largely did not account for heterogeneities between studies, additional undetected variables may account for heterogeneities which warrants further research. Secondly, in some of our analyses, only a very limited number of studies were available. For example, when focusing on the 12 mm size criterion, there was only one study available for evaluating CT with node unit, and future studies for evaluating relevant topics are warranted. In conclusion, through this comprehensive systematic review and meta-analysis, we identified that CT and MRI had acceptable diagnostic efficacy in detecting cervical lymph node metastasis in patients with head and neck cancer. When node was used as unit of analysis, CT had a higher SEN. When neck level was used as unit of analysis, MRI had a higher SPE. Out findings suggest that MRI is superior to CT in the diagnosis of cervical lymph node metastasis, especially in diagnosis confirmation. While CT had a better efficacy in diagnosis exclusion. The diagnostic criteria for MRI and CT for size of metastatic lymph nodes were established. Further high-quality studies are warranted to confirm our findings.

Supplementary materials
=======================

###### 

Meta-analysis of CT for detecting cervical lymph node metastasis in head and neck cancer patients (patient as unit of analysis).

**Abbreviations:** CT, computed tomography; CI, confidence interval; LR, likelihood ratio; *df*, degrees of freedom; SROC, summary receiver operating characteristic; AUC, area under the curve; SE, standard error.

###### 

Meta-analysis of MRI for detecting cervical lymph node metastasis in head and neck cancer patients (patient as unit of analysis) (retrospective studies).

**Abbreviations:** MRI, magnetic resonance imaging; CI, confidence interval; *df*, degrees of freedom; LR, likelihood ratio; OR, odds ratio.

###### 

Meta-analysis of MRI for detecting cervical lymph node metastasis in head and neck cancer patients (patient as unit of analysis) (prospective studies).

**Abbreviations:** MRI, magnetic resonance imaging; CI, confidence interval; *df*, degrees of freedom; LR, likelihood ratio; OR, odds ratio.

###### 

Meta-analysis of MRI for detecting cervical lymph node metastasis in head and neck cancer patients (patient as unit of analysis).

**Abbreviations:** MRI, magnetic resonance imaging; CI, confidence interval; *df*, degrees of freedom; LR, likelihood ratio; OR, odds ratio; SROC, summary receiver operating characteristic; AUC, area under the curve; SE, standard error.

###### 

Study characteristics of lymph node size per neck level

  Study ID                                      Method   Unit             I    II   III   IV   Retro   Others   TP    FP    FN   TN
  --------------------------------------------- -------- ---------------- ---- ---- ----- ---- ------- -------- ----- ----- ---- -----
  Adams et al[@b64-ott-8-1291] 1998             CT       node             12   12   12    12   12      12       96    175   21   992
  Adams et al[@b64-ott-8-1291] 1998             MRI      node             12   12   12    12   12      12       94    250   23   917
  Akoglu et al[@b65-ott-8-1291] 2005            CT       node             15   15   15    15   15      15       21    2     6    12
  Akoglu et al[@b65-ott-8-1291] 2005            MRI      node             15   15   15    15   15      15       16    1     11   13
  Anzai et al[@b67-ott-8-1291] 1994             MRI      node             10   10   10    10   10      10       38    7     2    34
  Braams et al[@b70-ott-8-1291] 1995            CT       node             11   10   10    10   10      10       5     10    4    13
  Braams et al[@b70-ott-8-1291] 1995            MRI      node             10   11   10    10   10      10       5     6     10   134
  Braams et al[@b70-ott-8-1291] 1995            MRI      node             11   10   10    10   10      10       8     10    14   167
  Curtin et al[@b72-ott-8-1291] 1997            CT       neck level       5    5    5     5    5       5        57    415   1    62
  Curtin et al[@b72-ott-8-1291] 1997            CT       neck level       7    7    7     7    7       7        56    396   2    81
  Curtin et al[@b72-ott-8-1291] 1997            CT       neck level       8    8    8     8    8       8        55    372   3    105
  Curtin et al[@b72-ott-8-1291] 1997            CT       neck level       9    9    9     9    9       9        53    329   5    148
  Curtin et al[@b72-ott-8-1291] 1997            CT       neck level       10   10   10    10   10      10       51    291   7    186
  Curtin et al[@b72-ott-8-1291] 1997            CT       neck level       11   11   11    11   11      11       46    210   12   267
  Curtin et al[@b72-ott-8-1291] 1997            CT       neck level       12   12   12    12   12      12       43    157   15   320
  Curtin et al[@b72-ott-8-1291] 1997            CT       neck level       15   15   15    15   15      15       32    76    26   401
  Curtin et al[@b72-ott-8-1291] 1997            MRI      neck level       5    5    5     5    5       5        53    382   5    95
  Curtin et al[@b72-ott-8-1291] 1997            MRI      neck level       7    7    7     7    7       7        52    367   6    110
  Curtin et al[@b72-ott-8-1291] 1997            MRI      neck level       8    8    8     8    8       8        50    329   8    148
  Curtin et al[@b72-ott-8-1291] 1997            MRI      neck level       9    9    9     9    9       9        48    281   10   196
  Curtin et al[@b72-ott-8-1291] 1997            MRI      neck level       10   10   10    10   10      10       47    248   11   229
  Curtin et al[@b72-ott-8-1291] 1997            MRI      neck level       11   11   11    11   11      11       41    167   17   310
  Curtin et al[@b72-ott-8-1291] 1997            MRI      neck level       12   12   12    12   12      12       38    134   20   343
  Curtin et al[@b72-ott-8-1291] 1997            MRI      neck level       15   15   15    15   15      15       30    67    28   410
  Dammann et al[@b73-ott-8-1291] 2005           CT       neck level       10   10   10    10   10      10       32    17    8    236
  Dammann et al[@b73-ott-8-1291] 2005           MRI      neck level       10   10   10    10   10      10       37    14    3    239
  Ding et al[@b75-ott-8-1291] 2005              MRI      neck level       8    8    8     8    8       8        132   27    34   255
  Dirix et al[@b75-ott-8-1291] 2010             MR-DW    neck level       10   10   10    10   10      10       30    3     2    93
  Dirix et al[@b75-ott-8-1291] 2010             MR-DW    node             10   10   10    10   10      10       40    4     5    149
  Dirix et al[@b75-ott-8-1291] 2010             MR-DW    patient          10   10   10    10   10      10       13    2     0    6
  Eida et al[@b76-ott-8-1291] 2003              CT       node             8    9    6     7                     3     5     3    162
  Fan et al[@b77-ott-8-1291] 2006               CT       patient          10   11   10    10   10      10       23    11    4    4
  Fukunari et al[@b78-ott-8-1291] 2010          MR       node             10   10   10    10   10      10       19    13    0    66
  Gross et al[@b79-ott-8-1291] 2001             MR       node             11   10   10    10   10      10       143   22    6    39
  Gu et al[@b80-ott-8-1291] 2000                MRI      node             10   11   10    10   10      10       8     3     1    50
  Guenzel et al[@b81-ott-8-1291] 2013           MR       node             10   10   10    10   10      10       23    26    2    8
  Guenzel et al[@b81-ott-8-1291] 2013           MR       node             15   15   15    15   15      15       20    6     2    28
  Guo et al[@b82-ott-8-1291] 2006               MRI      node             10   10   10    10   10      10       8     3     1    36
  Hafidh et al[@b85-ott-8-1291] 2006            CT       node             10   10   10    10   10      10       8     10    12   2
  Hafidh et al[@b85-ott-8-1291] 2006            MRI      node             10   10   10    10   10      10       11    10    9    2
  Hao et al[@b84-ott-8-1291] 2000               MRI      node             15   15   10    10   10      10       30    2     11   38
  Kau et al[@b89-ott-8-1291] 1999               CT       neck level       15   15   15    15   15      15       6     17    1    17
  Kau et al[@b89-ott-8-1291] 1999               MRI      neck level       15   15   15    15   15      15       2     17    1    15
  Kau et al[@b89-ott-8-1291] 1999               CT       node             15   15   15    15   15      15       13    20    7    18
  Kau et al[@b89-ott-8-1291] 1999               MRI      node             15   15   15    15   15      15       23    22    3    15
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level I     5                                     8     28    0    22
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level I     6                                     8     18    0    32
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level I     7                                     8     10    1    39
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level I     8                                     8     5     1    44
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level I     9                                     8     1     1    48
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level I     10                                    5     0     2    51
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level I     5                                     8     24    0    26
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level I     6                                     8     16    0    34
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level I     7                                     8     7     0    43
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level I     8                                     8     6     0    44
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level I     9                                     8     1     1    48
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level I     10                                    6     0     4    48
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level II         5                                25    21    0    12
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level II         6                                25    19    0    14
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level II         7                                25    16    1    16
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level II         8                                25    10    2    21
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level II         9                                25    1     6    26
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level II         10                               24    0     6    28
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level II         5                                25    22    0    11
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level II         6                                25    19    1    13
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level II         7                                25    19    1    13
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level II         8                                25    11    1    21
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level II         9                                25    6     2    25
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level II         10                               25    4     2    27
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level III             5                  5        15    7     0    36
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level III             6                  6        15    4     2    37
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level III             7                  7        15    2     2    39
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level III             8                  8        15    2     2    39
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level III             9                  9        13    0     3    42
  Kawai et al[@b90-ott-8-1291] 2005             MRSPIR   neck level III             10                 10       12    0     3    43
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level III             5                  5        15    10    0    33
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level III             6                  6        15    8     1    34
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level III             7                  7        15    3     4    36
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level III             8                  8        15    2     4    37
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level III             9                  9        11    0     4    43
  Kawai et al[@b90-ott-8-1291] 2005             MRSTIR   neck level III             10                 10       8     0     7    43
  Ke et al[@b91-ott-8-1291] 2006                CT       node             15   10   10    10   10      10       10    3     3    4
  Laubenbacher et al[@b93-ott-8-1291] 1994      MRI      neck level       15   15   15    15   15      15       13    7     5    9
  Laubenbacher et al[@b93-ott-8-1291] 1994      MRI      node             15   15   15    15   15      15       65    126   18   312
  Lee et al[@b94-ott-8-1291] 2013               MR-DW    patient          2    2    2     2    2       2        7     3     1    11
  Lee et al[@b94-ott-8-1291] 2013               MR-TSE   patient          2    2    2     2    2       2        7     6     1    8
  Lu et al[@b95-ott-8-1291] 2007                CT       node             15   10   10    19   10      10       11    1     3    6
  Lwin et al[@b96-ott-8-1291] 2012              MR       patient          10   15   10    10   5       10       63    82    15   24
  Mcguirt et al[@b97-ott-8-1291] 1995           CT       node             15   15   10    10   10      10       18    3     1    19
  Nakamoto et al[@b98-ott-8-1291] 2009          MRI      patient          10   10   10    10   10      10       16    2     4    30
  Olmos et al[@b100-ott-8-1291] 1999            MRI      neck level       10   10   10    10   10      10       22    11    2    27
  Paulus et al[@b102-ott-8-1291] 1998           CT       node             15   15   10    10   10      10       8     1     0    4
  Peters et al[@b104-ott-8-1291] 2013           CT       patient          3    3    3     3    3       3        10    56    0    1
  Peters et al[@b104-ott-8-1291] 2013           CT       patient          4    4    4     4    4       4        8     48    2    9
  Peters et al[@b104-ott-8-1291] 2013           CT       patient          5    5    5     5    5       5        6     29    4    28
  Peters et al[@b104-ott-8-1291] 2013           CT       patient          6    6    6     6    6       6        5     18    5    39
  Peters et al[@b104-ott-8-1291] 2013           CT       patient          7    7    7     7    7       7        5     6     5    51
  Peters et al[@b104-ott-8-1291] 2013           CT       patient          8    8    8     8    8       8        4     5     6    52
  Peters et al[@b104-ott-8-1291] 2013           CT       patient          9    9    9     9    9       9        3     1     7    56
  Peters et al[@b104-ott-8-1291] 2013           CT       patient          10   10   10    10   10      10       3     1     7    56
  Ren et al[@b106-ott-8-1291] 2000              CT       node             5    5    5     5    5       5        36    9     2    11
  Schwartz et al[@b107-ott-8-1291] 2004         CT       node             10   15   10    10   10      10       21    1     6    68
  Semedo et al[@b108-ott-8-1291] 2006           MR       node             10   10   10    10   10      10       24    8     1    30
  Seitz et al[@b109-ott-8-1291] 2009            MR       node             10   10   10    10   5       10       92    6     12   18
  Tai et al[@b116-ott-8-1291] 2002              MRI      patient          11   10   10    10   10      10       3     1     10   2
  Van den Brekel et al[@b119-ott-8-1291] 1991   MRI      neck level       10   10   10    10   10      10       87    13    42   415
  Van den Brekel et al[@b119-ott-8-1291] 1991   MRI      patient          10   10   10    10   10      10       63    6     15   46
  Vandecaveye et al[@b120-ott-8-1291] 2008      MR-TSE   neck level       10   10   10    10   10      10       27    10    20   208
  Vandecaveye et al[@b120-ott-8-1291] 2008      MR-TSE   node             10   10   10    10   10      10       34    10    40   217
  Vandecaveye et al[@b120-ott-8-1291] 2008      MR-TSE   patient          10   10   10    10   10      10       20    5     1    7
  Wang et al[@b121-ott-8-1291] 1999             MRI      node             10   10   10    10   10      10       23    0     15   130
  WIDE et al[@b122-ott-8-1291] 1999             MRI      neck level       10   15   10    10   10      10       18    11    9    34
  Wilson et al[@b123-ott-8-1291] 1994           MRI      neck level       5    5    5     5    5       5        17    16    0    18
  Wu et al[@b124-ott-8-1291] 2010               CT       node             8    8    8     8    8       8        10    1     2    11
  Yoon et al[@b125-ott-8-1291] 2008             CT       neck level       15   15   10    10   10      10       57    2     17   326
  Yoon et al[@b125-ott-8-1291] 2008             MRI      neck level       15   15   10    10           10       57    2     17   326
  Yuan et al[@b126-ott-8-1291] 2000             MRI      neck level       12   12   10    10   10      10       12    1     2    9

**Abbreviations:** MRI, magnetic resonance imaging; CT, computed tomography; MR-TSE,; MR-DW,; MRSTIR,; MRSPIR,; TP, true positive; FP, false positive; TN, true negative.

###### 

Meta-analysis results on diagnostic efficacy of MRI on size of metastatic lymph nodes

  Unit        Node size (mm)         SEN (95% CI)           SPE (95% CI)           AUC (SE)          Q\* (SE)
  ----------- ---------------------- ---------------------- ---------------------- ----------------- -----------------
  Level I     10                     0.768 (0.725--0.808)   0.901 (0.880--0.919)   0.9159 (0.0348)   0.8487 (0.0394)
  11          0.883                  0.866                                                           
  12          0.803                  0.786                                                           
  15          0.774 (0.709--0.830)   0.721 (0.682--0.758)   0.8653 (0.0295)        0.7959 (0.0287)   
  Level II    10                     0.812 (0.778--0.844)   0.883 (0.861--0.902)   0.9151 (0.0341)   0.8477 (0.0385)
  11          0.542                  0.953                                                           
  12          0.803                  0.786                                                           
  15          0.774 (0.709--0.830)   0.721 (0.682--0.758)   0.8653 (0.0295)        0.7959 (0.0287)   
  Level III   10                     0.801 (0.767--0.833)   0.894 (0.875--0.911)   0.9121 (0.0314)   0.8444 (0.0350)
  12          0.803                  0.786                                                           
  15          0.785 (0.712--0.846)   0.704 (0.662--0.742)   0.8385 (0.0274)        0.7705 (0.0253)   
  Level IV    10                     0.801 (0.767--0.833)   0.894 (0.875--0.911)   0.9121 (0.0314)   0.8444 (0.0350)
  12          0.803                  0.786                                                           
  15          0.785 (0.712--0.846)   0.704 (0.662--0.742)   0.8385 (0.0274)        0.7705 (0.0253)   
  Retro       5                      0.885                  0.750                                    
  10          0.780 (0.742--0.814)   0.899 (0.880--0.915)   0.9138 (0.0315)        0.8464 (0.0354)   
  12          0.803                  0.786                                                           
  15          0.785 (0.712--0.846)   0.704 (0.662--0.742)   0.8385 (0.0274)        0.7705 (0.0253)   
  Others      10                     0.801 (0.767--0.833)   0.894 (0.875--0.911)   0.9121 (0.0314)   0.8444 (0.0350)
  12          0.803                  0.786                                                           
  15          0.785 (0.712--0.846)   0.704 (0.662--0.742)   0.8385 (0.0274)        0.7705 (0.0253)   

**Abbreviations:** MRI, magnetic resonance imaging; SEN, sensitivity; CI, confidence interval; SPE, specificity; AUC, area under the curve; SE, standard error.

###### 

Meta-analysis results on diagnostic efficacy of CT on size of metastatic lymph nodes

  Unit        Node size (mm)         SEN (95% CI)           SPE (95% CI)      AUC (SE)          Q\* (SE)
  ----------- ---------------------- ---------------------- ----------------- ----------------- ----------
  Level I     5                      0.947                  0.550                               
  8           0.722 (0.465--0.903)   0.966 (0.928--0.988)                                       
  10          0.617 (0.464--0.755)   0.864 (0.770--0.930)                                       
  11          0.556                  0.565                                                      
  12          0.821                  0.850                                                      
  15          0.802 (0.711--0.875)   0.677 (0.573--0.771)   0.8519 (0.0818)   0.7830 (0.0776)   
  Level II    5                      0.947                  0.550                               
  8           0.769                  0.917                                                      
  9           0.500                  0.970                                                      
  10          0.607 (0.468--0.735)   0.510 (0.363--0.656)   0.7272 (0.1426)   0.6747 (0.1157)   
  11          0.556                  0.565                                                      
  12          0.821                  0.850                                                      
  15          0.802 (0.711--0.875)   0.818 (0.746--0.876)   0.9083 (0.0599)   0.8402 (0.0658)   
  Level III   5                      0.947                  0.550                               
  6           0.500                  0.970                                                      
  8           0.500                  0.970                                                      
  10          0.746 (0.659--0.820)   0.809 (0.739--0.867)   0.8499 (0.0783)   0.7811 (0.0740)   
  12          0.821                  0.850                                                      
  15          0.723 (0.574--0.844)   0.577 (0.432--0.713)                                       
  Level IV    5                      0.947                  0.550                               
  7           0.500                  0.970                                                      
  8           0.500                  0.970                                                      
  10          0.746 (0.659--0.820)   0.809 (0.739--0.867)   0.8499 (0.0783)   0.7811 (0.0740)   
  12          0.821                  0.850                                                      
  15          0.723 (0.574--0.844)   0.577 (0.432--0.713)                                       
  Retro       5                      0.947                  0.550                               
  8           0.500                  0.970                                                      
  10          0.746 (0.659--0.820)   0.809 (0.739--0.867)   0.8499 (0.0783)   0.7811 (0.0740)   
  12          0.821                  0.850                                                      
  15          0.723 (0.574--0.844)   0.577 (0.432--0.713)                                       
  Others      5                      0.947                  0.550                               
  8           0.500                  0.970                                                      
  10          0.746 (0.659--0.820)   0.809 (0.739--0.867)   0.8499 (0.0783)   0.7811 (0.0740)   
  12          0.821                  0.850                                                      
  15          0.723 (0.574--0.844)   0.577 (0.432--0.713)                                       

**Abbreviations:** CT, computed tomography; SEN, sensitivity; CI, confidence interval; SPE, specificity; AUC, area under the curve; SE, standard error.
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###### 

Signaling questions in the QUADAS-2

  Domain                                            Patient selection                                            Index test                                                                                               Reference standard                                                               Flow and timing
  ------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Signaling questions (yes/no/unclear)              1 Was a consecutive or random sample of patients enrolled?   4 Were the index test results inter preted without knowledge of the results of the reference standard?   5 Is the reference standard likely to correctly classify the target condition?   7 Was there an appropriate interval between index test(s) and reference standard?
  2 Was a case-control design avoided?                                                                           6 Were the reference standard results interpreted without know ledge of the results of the index test?   8 Did all patients receive a reference standard?                                 
  3 Did the study avoid inappropriate exclusions?                                                                                                                                                                         9 Were all patients included in the analysis?                                    

**Abbreviation:** QUADAS-2, The Quality Assessment Diagnostic Accuracy Studies statement-2.

###### 

Study characteristics and included data sets for CT and MRI of the included articles

  Study ID                                     Country                      Study type   Patients (M/F)   Age (yr), mean (range)   Tumor location                                                                         Imaging modality   Unit
  -------------------------------------------- ---------------------------- ------------ ---------------- ------------------------ -------------------------------------------------------------------------------------- ------------------ ---------------------------
  Adams et al[@b28-ott-8-1291] 1998            Germany                      P            60 (16/44)       58.3 (38--76)            Tongue, FOM, Palate, MAN, MAX                                                          MRI, CT            node
  Akoglu et al[@b29-ott-8-1291] 2005           Turkey                       P            23 (19/4)        58.3 (40--78)            Head and neck                                                                          MRI, CT            node
  Anzai et al[@b30-ott-8-1291] 1994            USA                          P            12 (7/5)         39--78                   EAC, MAN, BCC, RMT, Lip, Oral cavity, Larynx                                           MRI                node
  Ao et al[@b31-ott-8-1291] 1998               Japan                        R            42 (9/33)        60 (39--78)              Larynx                                                                                 MRI, CT            node
  Bondt et al[@b32-ott-8-1291] 2009            The Netherlands              P            16 (9/7)         40--77                   Tongue, NP, RMT, SMG, Cheek, RMT, SP, Nose                                             MRI, CT            neck level
  Braams et al[@b33-ott-8-1291] 1996           The Netherlands              P            11 (7/4)         62.3 (46--73)            FOM, RMT, Cheek, Gingiva                                                               MRI, CT            node
  Braams et al[@b34-ott-8-1291] 1995           The Netherlands              P            12 (8/4)         65.3 (48--85)            Tongue, Lip, Gingiva, RMT, FOM                                                         MRI                node
  Bruschini et al[@b35-ott-8-1291] 2003        Italy                        P            22 (19/3)        62.3 (46--79)            Larynx, OP, Oral cavity, Skin                                                          CT                 node
  Curtin et al[@b36-ott-8-1291] 1997           Canada                       R            213 (150/63)     59.6 (18--84)            Oral cavity, OP, HP, Larynx                                                            MRI, CT            neck level
  Dammann et al[@b37-ott-8-1291] 2005          Germany                      P            64 (43/21)       56 (26--83)              Oral cavity, OP                                                                        MRI, CT            neck level
  Ding et al[@b38-ott-8-1291] 2005             People's Republic of China   P            92 (58/34)       53 (24--81)              Tongue                                                                                 MRI                neck level
  Dirix et al[@b39-ott-8-1291] 2010            Sweden                       P            22 (13/9)        60 (41--83)              Oral cavity, Larynx, HP                                                                MRI                node
  Eida et al[@b40-ott-8-1291] 2003             Japan                        P            111 (74/37)                               FOM, Tongue, Palate, Gingiva, Cheek                                                    CT                 node
  Fan et al[@b41-ott-8-1291] 2006              People's Republic of China   R            42 (37/5)        53.6 (45--70)            OP, HP, Cervical esophageal                                                            CT                 patient
  Fukunari et al[@b42-ott-8-1291] 2010         Japan                        R            20               58 (23--81)              Tongue, Gingiva, Buccal, MAN, FOM                                                      MRI                node
  Gross et al[@b43-ott-8-1291] 2001            USA                          R            26 (8/18)        40 (10--80)              Thyroid                                                                                MRI                node
  Gu et al[@b44-ott-8-1291] 2000               People's Republic of China   P            62               58 (44--77)              Head and neck                                                                          MRI                node
  Guenzel et al[@b45-ott-8-1291] 2013          Germany                      P            120 (95/25)      41--85                   OP, Larynx                                                                             MRI                node
  Guo et al[@b46-ott-8-1291] 2006              People's Republic of China   R            48 (28/20)       56 (21--66)              Tongue, Buccal, Gingiva, FOM, Palate                                                   MRI                node
  Hannah et al[@b47-ott-8-1291] 2002           Australia                    P            48 (34/14)       61 (26--92)              Oral cavity, OP, SGL, HP                                                               CT                 neck level
  Hao et al[@b48-ott-8-1291] 2000              People's Republic of China   P            60                                        Tongue, Gingiva, FOM, Palate, RMT, Buccal, Larynx, HP                                  MRI                node
  Hafidh et al[@b49-ott-8-1291] 2006           Ireland                      R            48 (42/6)        56 (32--80)              Oral cavity, OP, HP, Paranasal sinuses, Ear(skin)                                      MRI, CT            node
  Hlawitschka et al[@b50-ott-8-1291] 2002      Germany                      P            38 (28/10)       59 (41--89)              Tongue, Buccal, Palate, MAX                                                            MRI, CT            node
  Hoffman et al[@b51-ott-8-1291] 2000          USA                          P            9 (6/3)          43--76                   Oral cavity, OP, Lip                                                                   MRI                node, neck level
  Jeong et al[@b52-ott-8-1291] 2007            Greece                       R            47 (41/6)        56.3                     Oral cavity, Larynx, OP, HP, PG                                                        CT                 neck level
  Kau et al[@b53-ott-8-1291] 1999              Germany                      P            111 (95/16)      29--78                   Larynx, OP, LP, Lip, Ear                                                               MRI, CT            node, neck level
  Kawai et al[@b54-ott-8-1291] 2005            Japan                        P            29 (23/6)        60 (28--81)              Tongue, OP, NP, Larynx, Buccal, Palate, PG, Gingiva                                    MRI                neck level
  Ke et al[@b55-ott-8-1291] 2006               People's Republic of China   R            20 (15/5)        54.5 (31--69)            Tongue, Larynx, Thyroid gland                                                          CT                 node
  Krabbe et al[@b56-ott-8-1291] 2008           The Netherlands              P            38 (21/17)       59 (53--680)             Tongue, Gingiva, FOM, Tonsillar fossa                                                  MRI, CT            node
  Laubenbacher et al[@b57-ott-8-1291] 1994     Germany                      P            22 (20/2)        54.4 (38--70)            OP, HP                                                                                 MRI                node, neck level
  Lee et al[@b58-ott-8-1291] 2013              People's Republic of China   P            22 (21/1)        49.8 (26--66)            Tongue, Buccal, OP, FOM, HP, Palate, RMT, epiglottis, Pyriform sinus                   MRI                patient
  Lu et al[@b59-ott-8-1291] 2007               People's Republic of China   P            13 (11/2)        58 (47--71)              Oral cavity, HP, OP, Larynx                                                            CT                 node
  Lwin et al[@b60-ott-8-1291] 2012             UK                           R            102 (68/34)      59 (23--89)              Tongue, FOM, Palate, Buccal, RMT, Tonsil, Gingiva                                      MRI                patient
  Mcguirt et al[@b61-ott-8-1291] 1995          UK                           P            49                                        Oral cavity, OP, HP                                                                    CT                 node
  Nakamoto et al[@b62-ott-8-1291] 2009         Japan                        R            65 (50/15)       62 (27--81)              Larynx, HP, MAX, Tongue, OP, PG, Gingiva, FOM, NP, Ethmoid, EAM, Thyoid                MRI                patient
  Nishimura et al[@b63-ott-8-1291] 2006        Japan                        P            16 (13/3)        65.8 (37--76)            Cervical Esophageal                                                                    MRI                node
  Olmos et al[@b64-ott-8-1291] 1999            The Netherlands              P            12 (6/6)         61.8 (44--73)            OP, Larynx, HP, Tongue, MAX                                                            MRI                neck level
  Ou et al[@b65-ott-8-1291] 2007               People's Republic of China   R            24 (19/5)        50 (23--80)              Tongue, OP, Palate, Cheek, Maxillary sinus, Branchial cleft                            MRI                node
  Paulus et al[@b66-ott-8-1291] 1998           Belgium                      R            25 (21/4)        48--74                   SGL, Tongue, Glottis, Palate, RMT, FOM, HP, Vocal cord, Vestibule, Pyriform sinus      CT                 node
  Perrone et al[@b67-ott-8-1291] 2011          Italy                        R            17 (10/7)        63 (15--85)              Head and neck                                                                          MRI                patient
  Peters et al[@b68-ott-8-1291] 2013           The Netherlands              R            149 (120/29)     62 (40--78)              SGL, Glottis, NP, Cervical Esophageal                                                  MRI, CT            patient
  Pohar et al[@b69-ott-8-1291] 2006            USA                          R            25 (17/8)        63.4                     Oral cavity, OP, HP, Larynx, Nasal cavity                                              CT                 node, neck level
  Ren et al[@b70-ott-8-1291] 2000              People's Republic of China   P            20 (18/2)        45--68                   SGL                                                                                    CT                 node
  Schwartz et al[@b71-ott-8-1291] 2004         USA                          P            20 (20/0)        61 (42--78)              Oral cavity, OP                                                                        CT                 node
  Semedo et al[@b72-ott-8-1291] 2006           Portugal                     P            20 (20/0)        57.3 (36--78)            HP, Larynx, OP                                                                         MRI                node
  Seitz et al[@b73-ott-8-1291] 2009            Germany                      R            66 (39/27)       63 (25--89)              Oral cavity, OP                                                                        MRI                node, patient
  Stokkel et al[@b74-ott-8-1291] 2000          The Netherlands              P            54 (31/23)       60 (34--81)              Tongue, FOM, Gingiva, RMT, OP                                                          CT                 node
  Stuckensen et al[@b75-ott-8-1291] 2000       Germany                      P            106 (89/17)      59.6 (33--87)            FOM, Tongue, RMT, MAN, MAX, Buccal                                                     MRI, CT            neck level
  Sumi et al[@b76-ott-8-1291] 2007             Japan                        R            38 (32/6)        65                       HP, Gingiva, OP, Tongue, Larynx, FOM                                                   MRI, CT            node
  Sumi et al[@b77-ott-8-1291] 2006             Japan                        P            26                                        OP, Gingiva, Larynx, Tongue                                                            MRI                node
  Sumi et al[@b78-ott-8-1291] 2003             Japan                        P            32               24--80                   OP, Gingiva, FOM, Tongue, Buccal, EAC                                                  MRI                node
  Sun et al[@b79-ott-8-1291] 2013              People's Republic of China   R            114 (60/54)      51.2 (34--70)            Thyroid gland, Larynx, NP, HP, Tongue, PG, Cervical Esophageal, Maxillary sinus, Ear   CT                 node
  Sun et al[@b79-ott-8-1291] 2013              People's Republic of China   R            86 (45/41)       52.7 (35--75)            Thyroid gland, Larynx, NP, HP, Tongue, PG, Cervical Esophageal, Maxillary sinus, Ear   MRI                node
  Tai et al[@b80-ott-8-1291] 2002              People's Republic of China   P            40 (24/16)       25--65                   NP                                                                                     MRI                patient
  Takashima et al[@b81-ott-8-1291] 1997        Japan                        R            50 (13/37)       57 (24--81)              Thyroid                                                                                MRI                node
  Tuli et al[@b82-ott-8-1291] 2008             India                        P            20 (12/8)        54.75 (30--85)           Tongue                                                                                 MRI, CT            patient
  Van den Brekel et al[@b83-ott-8-1291] 1991   The Netherlands              P            100              63±12.8                  Tongue, FOM, SP, Lip, Tonsil, Pharyngeal wall, Ear, Tonsil, PS, SGL, Gingiva           MRI                patient
  Vandecaveye et al[@b84-ott-8-1291] 2008      Belgium                      P            36               41--81                   Nasal cavity, SGL, FOM, OP, Glottis, Tongue, HP                                        MRI                node, neck level, patient
  Wang et al[@b85-ott-8-1291] 1999             Japan                        P            14 (10/4)        46 (26--71)              Thyroid                                                                                MRI                node
  WIDE et al[@b86-ott-8-1291] 1999             UK                           R            58               58.1 (32--82)            Tongue, FOM, Buccal, RMT, OP, Gingiva                                                  MRI                neck level
  Wilson et al[@b87-ott-8-1291] 1994           UK                           P            12                                        FOM, Tongue, Tonsillar, Skin, Pinna, PG, Thyroid                                       MRI                neck level
  Wu et al[@b88-ott-8-1291] 2010               People's Republic of China   R            24 (23/1)        53.6 (45--85)            Larynx, HP                                                                             CT                 node
  Yoon et al[@b89-ott-8-1291] 2008             Korea                        R            67 (58/9)        60 (24--85)              Larynx, Pharynx, Tonsil, Tongue, Oral cavity, Skin, MAX                                MRI, CT            neck level
  Yuan et al[@b90-ott-8-1291] 2000             People's Republic of China   R            19 (12/7)        42--66                   Larynx                                                                                 MRI                neck level

**Abbreviations:** M, male; F, female; R, Retrospective; P, Prospective; EAC, external auditory canal; BCC, branchial cleft cyst; PS, piriform sinus; SGL, supra-glottic larynx; TGL, trans-glottic larynx; CT, computed tomography; MRI, magnetic resonance imaging; FOM, floor of mouth; MAN, mandibule; MAX, maxilla; RMT, retro-molar trigonum; NP, nasopharynx; SMG, submandibular gland; OP, oropharynx; HP, hypopharynx; LP, laryngopharynx; PG, parotid gland; SP, supropharynx; yr, years.

###### 

Risk of bias of included studies

  Study ID                                     Patient selection   Index test   Reference standard   Flow and timing   Summary risk of bias   Applicability                   
  -------------------------------------------- ------------------- ------------ -------------------- ----------------- ---------------------- --------------- --- --- --- --- ---
  Adams et al[@b28-ott-8-1291] 1998            U                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Akoglu et al[@b29-ott-8-1291] 2005           Y                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Anzai et al[@b30-ott-8-1291] 1994            U                   Y            Y                    U                 Y                      U               Y   Y   Y   B   H
  Ao et al[@b31-ott-8-1291] 1998               U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Bondt et al[@b32-ott-8-1291] 2009            Y                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Braams et al[@b33-ott-8-1291] 1996           U                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Braams et al[@b34-ott-8-1291] 1995           U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Bruschini et al[@b35-ott-8-1291] 2003        U                   Y            Y                    Y                 Y                      Y               U   Y   Y   B   H
  Curtin et al[@b36-ott-8-1291] 1997           Y                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Dammann et al[@b37-ott-8-1291] 2005          U                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Ding et al[@b38-ott-8-1291] 2005             U                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Dirix et al[@b39-ott-8-1291] 2010            U                   Y            Y                    U                 Y                      U               Y   Y   Y   B   H
  Eida et al[@b40-ott-8-1291] 2003             U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Fan et al[@b41-ott-8-1291] 2006              U                   Y            Y                    Y                 Y                      U               U   Y   N   A   H
  Fukunari et al[@b42-ott-8-1291] 2010         U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Gross et al[@b43-ott-8-1291] 2001            U                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Gu et al[@b44-ott-8-1291] 2000               U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Guenzel et al[@b45-ott-8-1291] 2013          U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Guo et al[@b46-ott-8-1291] 2006              U                   Y            Y                    U                 Y                      U               U   Y   N   A   H
  Hannah et al[@b47-ott-8-1291] 2002           U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Hao et al[@b48-ott-8-1291] 2000              U                   Y            Y                    Y                 Y                      Y               U   Y   Y   B   H
  Hafidh et al[@b49-ott-8-1291] 2006           U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Hlawitschka et al[@b50-ott-8-1291] 2002      Y                   Y            Y                    U                 Y                      U               U   Y   N   A   H
  Hoffman et al[@b51-ott-8-1291] 2000          U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Jeong et al[@b52-ott-8-1291] 2007            U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Kau et al[@b53-ott-8-1291] 1999              Y                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Kawai et al[@b54-ott-8-1291] 2005            Y                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Ke et al[@b55-ott-8-1291] 2006               Y                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Krabbe et al[@b56-ott-8-1291] 2008           U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Laubenbacher et al[@b57-ott-8-1291] 1994     U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Lee et al[@b58-ott-8-1291] 2013              Y                   Y            Y                    U                 Y                      U               Y   Y   Y   B   H
  Lu et al[@b59-ott-8-1291] 2007               Y                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Lwin et al[@b60-ott-8-1291] 2012             U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Mcguirt et al[@b61-ott-8-1291] 1995          Y                   Y            Y                    U                 Y                      Y               U   Y   Y   B   H
  Nakamoto et al[@b62-ott-8-1291] 2009         U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Nishimura et al[@b63-ott-8-1291] 2006        Y                   Y            Y                    U                 Y                      U               Y   Y   Y   B   H
  Olmos et al[@b64-ott-8-1291] 1999            U                   Y            Y                    U                 Y                      U               Y   Y   N   A   H
  Ou et al[@b65-ott-8-1291] 2007               U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Paulus et al[@b66-ott-8-1291] 1998           U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Perrone et al[@b67-ott-8-1291] 2011          U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Peters et al[@b68-ott-8-1291] 2013           U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Pohar et al[@b69-ott-8-1291] 2006            Y                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Ren et al[@b70-ott-8-1291] 2000              U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Schwartz et al[@b71-ott-8-1291] 2004         U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Semedo et al[@b72-ott-8-1291] 2006           Y                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Seitz et al[@b73-ott-8-1291] 2009            Y                   Y            Y                    Y                 Y                      Y               Y   Y   Y   C   H
  Stokkel et al[@b74-ott-8-1291] 2000          U                   Y            Y                    U                 Y                      U               Y   Y   Y   B   H
  Stuckensen et al[@b75-ott-8-1291] 2000       Y                   Y            Y                    U                 Y                      U               Y   Y   Y   B   H
  Sumi et al[@b76-ott-8-1291] 2007             U                   Y            Y                    U                 Y                      U               Y   Y   Y   B   H
  Sumi et al[@b77-ott-8-1291] 2006             Y                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Sumi et al[@b78-ott-8-1291] 2003             Y                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Sun et al[@b79-ott-8-1291] 2013              Y                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Tai et al[@b80-ott-8-1291] 2002              U                   Y            Y                    Y                 Y                      U               U   Y   N   A   H
  Takashima et al[@b81-ott-8-1291] 1997        U                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Tuli et al[@b82-ott-8-1291] 2008             Y                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Van den Brekel et al[@b83-ott-8-1291] 1991   U                   Y            Y                    Y                 Y                      U               Y   Y   Y   B   H
  Vandecaveye et al[@b84-ott-8-1291] 2008      Y                   Y            Y                    Y                 Y                      Y               U   Y   Y   B   H
  Wang et al[@b85-ott-8-1291] 1999             U                   Y            Y                    Y                 Y                      Y               Y   Y   Y   C   H
  WIDE et al[@b86-ott-8-1291] 1999             U                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Wilson et al[@b87-ott-8-1291] 1994           Y                   Y            Y                    Y                 Y                      U               U   Y   Y   B   H
  Wu et al[@b88-ott-8-1291] 2010               U                   Y            Y                    U                 Y                      U               U   Y   Y   B   H
  Yoon et al[@b89-ott-8-1291] 2008             U                   Y            Y                    U                 Y                      U               Y   Y   Y   B   H
  Yuan et al[@b90-ott-8-1291] 2000             U                   Y            Y                    U                 Y                      U               Y   Y   Y   B   H

**Abbreviations:** Y, yes; U, unclear; N, no; A, high risk of bias; B, unclear risk of bias; C, low risk of bias; H, high applicability.

###### 

Comparison of meta-analysis results on diagnostic efficacy between CT and MRI

  Unit         Variable   Number detected     SEN (95% CI)        SPE (95% CI)        AUC (SE)          Q\* (SE)
  ------------ ---------- ------------------- ------------------- ------------------- ----------------- -----------------
  Node         CT         2,483               0.77 (0.73--0.87)   0.85 (0.84--0.87)   0.8429 (0.0341)   0.7745 (0.0318)
  MRI          7,100      0.72 (0.70--0.74)   0.84 (0.83--0.85)   0.9054 (0.0198)     0.8371 (0.0215)   
  *P*                     0.0176              0.2739              0.1098              0.1262            
  Neck level   CT         1,665               0.84 (0.75--0.84)   0.72 (0.69--0.74)   0.8787 (0.0268)   0.8091 (0.0270)
  MRI          4,022      0.80 (0.77--0.82)   0.81 (0.80--0.82)   0.8860 (0.0262)     0.8165 (0.0269)   
  *P*                     1.0000              0.0000              0.8689              0.8702            
  Patient      CT         230                 0.67 (0.52--0.80)   0.74 (0.68--0.81)   0.6860 (0.0815)   0.6418 (0.0643)
  MRI          716        0.78 (0.70--0.81)   0.76 (0.72--0.80)   0.8631 (0.0437)     0.7937 (0.0424)   
  *P*                     0.1992              0.6161              0.0491              0.0683            

**Abbreviations:** AUC, area under the curve; CI, confidence interval; SE, standard error; CT, computed tomography; MRI, magnetic resonance imaging; SEN, sensitivity; SPE, specificity.

###### 

Results of meta-regression (MRI patient)

  Variable                   Coefficient   SE       *P*-value   RDOR    95% CI
  -------------------------- ------------- -------- ----------- ------- ----------------
  Cte                        −0.511        2.5493   0.8539      --      --
  S                          −0.330        0.1896   0.1798      --      --
  Publication year           0.881         1.5156   0.6020      2.41    (0.02--300.01)
  Race                       1.786         1.1884   0.2298      5.97    (0.14--262.04)
  Study type                 3.288         0.9742   0.0432      26.80   (1.21--595.04)
  Blinding of radiologists   −0.774        1.1952   0.5636      0.46    (0.01--20.70)
  Blinding of pathologists   −0.290        1.5278   0.8615      0.75    (0.01--96.74)
  Risk of bias               −0.227        0.9225   0.8217      0.80    (0.04--15.02)

**Abbreviations:** MRI, magnetic resonance imaging; CI, confidence interval; SE, standard error; RDOR, relative diagnostic odds ratio.
